13 September 2023
Last month, PACFA’s CEO Johanna de Wever and Head of Practice Sophie Keramidopoulos met with key representatives of the Australian Multidisciplinary Association for Psychedelic Practitioners (AMAPP) regarding Psychedelic Assisted Therapy (PAT).
On the 1st of July 2023, the Therapeutic Goods Administration (TGA) rescheduled Psylocibin and MDMA from Schedule 9 to Schedule 8. This allowed them to be legally prescribed under very strict conditions for the treatment of Treatment-Resistant Depression (TRD) and Post Traumatic Stress Disorder (PTSD).
The AMAPP was formed to serve as the peak body for Psychedelic-Assisted Therapy in Australia. It aims to provide the framework for the safe, ethical, accountable and effective introduction of PAT, focusing on the best client outcomes.
PACFA is engaging in ongoing conversations with AMAPP and is aware that some of PACFA’s members are working closely with innovation in this field; we encourage interested PACFA members to join AMAPP.
Additionally, PACFA is compiling a list of interested members in the area of PAT with the expectation of increasing our support over the next 12-24 months as the work becomes more established and as PAT continues to progress further. Please email PACFA at [email protected] to express your interest in this area.